Collegium Pharmaceutical, Inc. $COLL Stock Holdings Decreased by Smith Group Asset Management LLC

Smith Group Asset Management LLC lowered its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 69.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,544 shares of the specialty pharmaceutical company’s stock after selling 51,352 shares during the quarter. Smith Group Asset Management LLC’s holdings in Collegium Pharmaceutical were worth $492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in COLL. Freestone Grove Partners LP bought a new position in Collegium Pharmaceutical in the second quarter worth about $1,611,000. Globeflex Capital L P bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $1,915,000. Empowered Funds LLC bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $2,045,000. Bank of America Corp DE bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $9,882,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Collegium Pharmaceutical in the 2nd quarter worth approximately $8,506,000.

Collegium Pharmaceutical Stock Up 1.0%

Shares of COLL stock opened at $23.23 on Thursday. The stock’s fifty day moving average price is $23.47 and its 200 day moving average price is $33.59. Collegium Pharmaceutical, Inc. has a 1-year low of $21.43 and a 1-year high of $50.79. The company has a market cap of $756.37 million, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 0.71 and a beta of 0.73. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same period last year, the business posted $1.68 earnings per share. On average, research analysts expect that Collegium Pharmaceutical, Inc. will post 6.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on COLL shares. Oppenheimer assumed coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price objective for the company. Barclays decreased their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, August 19th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Truist Financial began coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued a “buy” rating and a $49.00 target price for the company. Finally, Needham & Company LLC cut their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.